Deal Details

Sale to Eli Lilly and Company

---

Summary

About

AurKa Pharma, Inc. (“AurKa Pharma”), a portfolio company of TVM Capital Life Science (“TVM Capital”), was recently acquired by Eli Lilly and Company (“Lilly”) (NYSE:LLY) for $575 million in cash and contingent regulatory and sales milestones.

AurKa Pharma is a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that AurKa Pharma is studying in Phase I clinical trials in multiple types of solid tumors. AurKa Pharma is based in Montréal, Québec.

TVM Capital Life Science is a group of independent investment advisories and fund managers for Venture Capital funds, investing into innovative biotech, pharmaceutical and medtech companies with teams based in Munich and Montreal. Since 1984, TVM Capital has invested in more than 140 life science companies in Europe, Canada and the United States, currently managing in excess of US$1.1 billion from more than 50 investors.

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Lilly was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today remains true to that mission in all of its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease and give back to communities through philanthropy and volunteerism. Lilly is headquartered in Indianapolis, Indiana.

---

CONTACT US TO LEARN MORE